Skip to content
Shyenova

Industry 04

How far past your tier-one suppliers can you actually see?

The dependencies that stop a pharmaceutical line are rarely the ones on the supplier review agenda. They are low-spend, highly specialised, single-source, and invisible until they fail.

Pharmaceutical supply chains carry an unusual asymmetry: a stockout has a consequence that does not appear in any cost model, and excess carries an expiry clock that makes the usual buffer answer expensive. That combination makes the standard levers (hold more, run leaner) both wrong, and pushes the real answer toward positioning and dependency rather than quantity.

The second asymmetry is structural. Active ingredient supply is frequently concentrated in ways that a tier-one supplier view cannot see, with several nominally independent suppliers drawing on the same upstream source. Mapping that convergence is unglamorous and it is where the material risk in this sector actually sits.

What is changing

Four pressures worth naming.

Not a market overview. These are the specific things that make the standard answer wrong in this sector right now.

01Pressure

Concentration hides below tier one

Several qualified suppliers frequently resolve to one upstream producer of the active ingredient. Dual sourcing that has not been traced past the first tier is a paper hedge.

02Pressure

Expiry makes over-buffering expensive

The usual response to supply risk (hold more) carries a write-off clock here, which is why positioning and form matter far more than aggregate quantity.

03Pressure

Qualification lead times foreclose options

Bringing a second source online takes long enough that the decision has to be made well before the risk materialises, which means it competes for capital against things with visible returns.

04Pressure

Cold chain failure is silent until it is not

Excursions in distribution are frequently detected after the fact, and the cost of a compromised consignment is borne long after the temperature deviation that caused it.

Questions

About pharma & healthcare.

Our suppliers will not disclose their own suppliers. How do you map tier two?

Partly through commercial leverage, which works better than expected when the request is specific and framed around a named critical input rather than a blanket questionnaire. Beyond that, bill-of-material tracing, customs and shipping records, and plant-level registries. The map is never complete and does not need to be. It needs to cover the inputs whose failure would stop you.

Is holding more inventory the right answer to supply risk here?

Less often than in other sectors, because expiry gives the buffer a cost that compounds. Strategic stock works for stable, storable, long-lead-time items. For anything with a meaningful shelf-life constraint, dual qualification, design substitution or contracted flexible capacity usually buys more protection per rupee.

How do you price a risk whose worst case is not financial?

By separating the two. The financial exposure (lost revenue over the gap between time-to-recover and time-to-survive) is quantifiable and competes for capital normally. The clinical consequence is not, and should be handled as a constraint on the answer rather than a term inside it. Mixing them produces a number nobody believes.

Start a conversation

Talk to us about pharma & healthcare.

Most useful first conversations are thirty minutes and involve no proposal. Describe the problem you are looking at and we will tell you honestly whether it is one we can help with.

Or write directly to hello@shyenova.com